Archive: January, 2021

DOD Supports Phase III Clinical Trial Using Fostamatinib (TAVALISSE®) Against COVID-19
January 29, 2021

DOD Supports Phase II Clinical Trials Repurposing Inhaled PUL-042 for COVID-19 Prevention and Treatment
January 26, 2021

Increased Collaboration Promotes Improved Medical Diagnostic Capabilities and Health Outcomes
January 25, 2021

HHS, DOD purchase additional doses of Regeneron therapeutic to treat patients with mild to moderate COVID-19
January 12, 2021


Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.  



JPEO-CBRND Public Affairs Office

The JPEO-CBRND Communications Affairs Network coordinates and responds to all Public Affairs needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.